Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ezetimibe

FDA-approved product (tablet, oral), marketed as Ezetimibe, Zetia.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ezetimibe
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Familial hypercholesterolemia
  • Homozygous familial hypercholesterolemia
  • Hypercholesterolemia
  • Hyperlipidemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other lipid modifying agents
FDA pharmacologic class
Dietary Cholesterol Absorption Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ezetimibe in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ezetimibe with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE

    NCT07440381 · start 2026-09

    Registered record
    Registry ID
    NCT07440381
    Conditions
    Acute Coronary Syndromes; Secondary Prevention; Lipids
    Interventions
    Triple oral lipid lowering treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2027-08
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndromes; Secondary Prevention; Lipids
    InterventionTriple oral lipid lowering treatment
    PhasePhase 3
    Registry statusNot yet recruiting

  • Polypills Approach for Multiple Cardiovascular Risk Factors

    NCT07679828 · start 2026-07-11

    Registered record
    Registry ID
    NCT07679828
    Conditions
    Hypertension; Dyslipidemia; Diabetes
    Interventions
    Fixed-Dose Combination Strategy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-07-11
    Completion
    2030-03-01
    Enrolment
    8,252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Dyslipidemia; Diabetes
    InterventionFixed-Dose Combination Strategy
    PhaseNot applicable
    Registry statusRecruiting

  • A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

    NCT07622433 · start 2026-06-10

    Registered record
    Registry ID
    NCT07622433
    Conditions
    Healthy Participants
    Interventions
    Laroprovstat/ezetimibe FCDP; Laroprovstat STP; Ezetimibe STP; Laroprovstat/ezetimibe FCDP-slow variant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2026-06-10
    Completion
    2026-09-07
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionLaroprovstat/ezetimibe FCDP; Laroprovstat STP; Ezetimibe STP; Laroprovstat/ezetimibe FCDP-slow variant
    PhasePhase 1
    Registry statusActive not recruiting

  • GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification

    NCT06722521 · start 2025-07-09

    Registered record
    Registry ID
    NCT06722521
    Conditions
    Primary Prevention; Vascular Calcification
    Interventions
    Pitavastatin 4mg and ezetimibe 10mg, taken once daily; Pitavastatin 2 mg with aspirin 100 mg, taken once daily.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-07-09
    Completion
    2032-10-31
    Enrolment
    7,435

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Prevention; Vascular Calcification
    InterventionPitavastatin 4mg and ezetimibe 10mg, taken once daily; Pitavastatin 2 mg with aspirin 100 mg, taken once daily.
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study

    NCT07523971 · start 2025-06-25

    Registered record
    Registry ID
    NCT07523971
    Conditions
    Dyslipidemias
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-06-25
    Completion
    2027-06
    Enrolment
    10,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemias
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)

    NCT06231966 · start 2024-04-22

    Registered record
    Registry ID
    NCT06231966
    Conditions
    Peripheral Artery Disease; Polyvascular Disease
    Interventions
    Combination therapy of high-intensity dose rosuvastatin and ezetimibe; Rosuvastatin monotherapy for treat-to-target
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-04-22
    Completion
    2029-05-06
    Enrolment
    2,462

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Artery Disease; Polyvascular Disease
    InterventionCombination therapy of high-intensity dose rosuvastatin and ezetimibe; Rosuvastatin monotherapy for treat-to-target
    PhaseNot applicable
    Registry statusRecruiting

  • Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

    NCT06005597 · start 2024-03-01

    Registered record
    Registry ID
    NCT06005597
    Conditions
    Dyslipidemias; Hypercholesterolemia; Familial Hypercholesterolemia; ASCVD; High Cholesterol
    Interventions
    Combination Therapy; Monotherapy obicetrapib; Monotherapy ezetimibe; Combination Therapy placebo; Obicetrapib Placebo; Ezetimibe Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-03-01
    Completion
    2024-10-16
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemias; Hypercholesterolemia; Familial Hypercholesterolemia; ASCVD +1 more
    InterventionCombination Therapy; Monotherapy obicetrapib; Monotherapy ezetimibe; Combination Therapy placebo +2 more
    PhasePhase 3
    Registry statusCompleted

  • Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

    NCT06186037 · start 2024-02-01

    Registered record
    Registry ID
    NCT06186037
    Conditions
    Coronary Artery Disease; Dyslipidemias; Primary Prevention
    Interventions
    Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg; Mono drug group of Rosuvastatin 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-02-01
    Completion
    2029-02-28
    Enrolment
    6,356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Dyslipidemias; Primary Prevention
    InterventionCombination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg; Mono drug group of Rosuvastatin 20 mg
    PhasePhase 4
    Registry statusRecruiting

  • High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium

    NCT05845424 · start 2023-07-03

    Registered record
    Registry ID
    NCT05845424
    Conditions
    Coronary Artery Calcification; Metabolic Syndrome; Dyslipidemias
    Interventions
    Guideline directed statin therapy; High intensity statin plus ezetimibe therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-07-03
    Completion
    2030-06-30
    Enrolment
    6,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Calcification; Metabolic Syndrome; Dyslipidemias
    InterventionGuideline directed statin therapy; High intensity statin plus ezetimibe therapy
    PhasePhase 4
    Registry statusRecruiting

  • Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial

    NCT05705804 · start 2023-06-13

    Registered record
    Registry ID
    NCT05705804
    Conditions
    Dyslipidemias; Atherosclerotic Cardiovascular Disease
    Interventions
    Pitavastatin; Pitavastatin plus Ezetemibe; Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-06-13
    Completion
    2027-06-01
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemias; Atherosclerotic Cardiovascular Disease
    InterventionPitavastatin; Pitavastatin plus Ezetemibe; Atorvastatin
    PhaseNot applicable
    Registry statusRecruiting

  • Cholesterol Lowering and Residual Risk in Diabetes, Type 1

    NCT05641753 · start 2022-12-06

    Registered record
    Registry ID
    NCT05641753
    Conditions
    Type 1 Diabetes
    Interventions
    Evolocumab Cartridge; Atorvastatin Calcium Tablets; Ezetimibe Tablets; 18F-FDG; Angiocatheter 20IV; J-Wire; GlycoCheck Glycocalyx Measurement Software
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-12-06
    Completion
    2027-07-31
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes
    InterventionEvolocumab Cartridge; Atorvastatin Calcium Tablets; Ezetimibe Tablets; 18F-FDG +3 more
    PhasePhase 4
    Registry statusRecruiting

  • Statin and Bone Health

    NCT05613400 · start 2022-04-13

    Registered record
    Registry ID
    NCT05613400
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Simvastatin 10mg; Ezetimibe 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-04-13
    Completion
    2025-06-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionSimvastatin 10mg; Ezetimibe 10mg
    PhasePhase 4
    Registry statusUnknown

  • A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older

    NCT07489183 · start 2021-08-23

    Registered record
    Registry ID
    NCT07489183
    Conditions
    Hypercholesterolemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-08-23
    Completion
    2023-09-07
    Enrolment
    641

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia

    NCT04433533 · start 2021-01-06

    Registered record
    Registry ID
    NCT04433533
    Conditions
    Left Ventricular Diastolic Dysfunction; Hyperlipidemias
    Interventions
    Rosuvastatin 20; Rosuvamibe 10/10
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-01-06
    Completion
    2023-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeft Ventricular Diastolic Dysfunction; Hyperlipidemias
    InterventionRosuvastatin 20; Rosuvamibe 10/10
    PhasePhase 4
    Registry statusUnknown

  • To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia

    NCT04659070 · start 2020-07-15

    Registered record
    Registry ID
    NCT04659070
    Conditions
    Primary Hypercholesterolemia; Hypertension
    Interventions
    Experimental : Ezetimibe / Rosuvastatin + Telmisartan; Active comparator1 : Ezetimibe / Rosuvastatin; Active comparator2 : Telmisartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-07-15
    Completion
    2022-05-19
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Hypercholesterolemia; Hypertension
    InterventionExperimental : Ezetimibe / Rosuvastatin + Telmisartan; Active comparator1 : Ezetimibe / Rosuvastatin; Active comparator2 : Telmisartan
    PhasePhase 3
    Registry statusUnknown